Adaptimmune Therapeutics Plc ADR (ADAP) saw downtrend of 0.00% in the recent trading with $1.44 being its most recent. The current price level -29.76% lower than the highest price of $2.05 marked by the stock while trading over the past 52-weeks, whereas it is 242.86% higher than the lowest price of $0.42 the company dropped to over past 52-weeks. The latest news story on ADAP appeared in (GuruFocus.com) under the title “Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results”.
Squeezing the time span to 30 day period shows us the stock is currently trading -29.76% below one month high and is +16.13% above of the lowest during that time. Looking into the simple moving average, Adaptimmune Therapeutics Plc ADR (ADAP)’s stock stands at a SMA-50 of $1.2433 while that of 5-day is reading $1.3920.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ADAP’s SMA-200 as of now is $0.8652.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.14 for the stock.
Adaptimmune Therapeutics Plc ADR Earnings – What Happened With ADAP
Coming around sales and income figures on ADAP Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Adaptimmune Therapeutics Plc ADR (ADAP) last released financial results for the quarter that ended 12/30/2023, posting a surprise factor of -140.00% for net revenue.
ADAP – Adaptimmune Therapeutics Plc ADR Stock Earnings Estimates
The perspective of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.1 for stock’s EPS in the current quarter. 4 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.24.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 227.17 million. ADAP does have institutional investors; and they hold 58.64% of the stock.
Adaptimmune Therapeutics Plc ADR – Insider Activity and Holdings
As on Jun 29, 2023, Matrix Capital Management was the top most holder in Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) with an ownership of 38.97 million shares of the company or 25.20% of the stake worth $36.05 million. The filing also reveals Baillie Gifford and Company as the second largest holder in the company with a control over 11.11% of the outstanding shares. Its stake is worth $15.89 million for having 17.18 million shares in hand.
NEA Management Company, LLC also came holding a key position in the company during the recent quarter and it now holds 11.04% of the outstanding shares. With this there are now 93 institutions which have possession in ADAP’s shares.
Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.14 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Adaptimmune Therapeutics Plc ADR has a debt to equity ratio of 0.64.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Adaptimmune Therapeutics Plc ADR (ADAP), we notice that the stock’s 20-day average volume is at 2,077,265 shares and 50% of short term indicators are suggesting the stock as Buy. Medium term indicators at an average of 100% are spotting the stock at Buy with its 50-day average volume of 2,083,224 shares. And to end, ADAP’s 100-day average volume is 1,372,994 shares with 100% of the long-term indicators pointing towards Buy for the stock.
